The Delhi High Court has requested the Centre to present its position regarding a petition filed by a pharmaceutical company that challenges the government’s decision to ban the manufacture, sale, and distribution of certain Fixed Dose Combination (FDC) drugs for human use.
FDC drugs are those that contain a fixed ratio of two or more active pharmaceutical ingredients (APIs).
While issuing notices on three petitions filed by Glenmark Pharmaceuticals Ltd against the ban, the court has directed that the FDC drugs produced by the petitioners, which are already in the distribution channel, should not be withdrawn. It further ordered that no coercive measures be taken against the petitioners.
The Centre on Friday opposed a proposal in the Supreme Court to form a committee…
The Delhi High Court Bar Association on Friday honored Chief Justice of India Justice Sanjiv…
The International Criminal Court has recently issued arrest warrants for Israeli Prime Minister Benjamin Netanyahu,…
The Calcutta High Court on Friday granted an interim stay on the demolition of alleged…
The Supreme Court on Friday announced that it would deliver its order on November 25…
The Supreme Court raised concerns on Friday about the "drastic" consequences of the GRAP Stage…